Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 112

Sort by

Sort Order Select

Journal Articles

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A - and NPM1 -altered leukemias

Blood (2024) 144 (11): 1206–1220.

https://doi.org/10.1182/blood.2023022480

Published: 2024

Includes: Supplemental data

Journal Articles

PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway

Hao Gu, Chiqi Chen, Zhi-Shuai Hou, Xia-Di He, Shaozhen Xie, Jing Ni, Changli Qian, Xin Cheng, Tao Jiang, Ce Yang, Thomas M. Roberts, Junke Zheng, Judith A. Varner, Scott A. Armstrong, Jean J. Zhao

Blood (2024) 143 (19): 1965–1979.

https://doi.org/10.1182/blood.2023022202

Published: 2024

Includes: Supplemental data

Journal Articles

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A -r and NPM1c AML

Blood (2024) 143 (15): 1513–1527.

https://doi.org/10.1182/blood.2023021105

Published: 2024

Includes: Supplemental data

Journal Articles

BOD1L Facilitates Chromatin Binding of SETD1A and Promotes Leukemia Cell Growth

Takayuki Hoshii, Sota Kikuchi, Seito Shibata, Makoto Matsumoto, Bahityar Rahmutulla, Masaki Fukuyo, Scott A Armstrong, Atsushi Kaneda

Blood (2023) 142 (Supplement 1): 4114.

https://doi.org/10.1182/blood-2023-173799

Published: 2023

Journal Articles

Epitope Edited Hematopoietic Stem Cells to Enable Synergistic Immunotherapy Combinations for Acute Myeloid Leukemia

Gabriele Casirati, Andrea Cosentino, Adele Mucci, Mohammed S Mahmoud, Iratxe Ugarte Zabala, Jing Zeng, Scott Ficarro, Denise Klatt, Christian Brendel, Alessandro Rambaldi, Jerome Ritz, Jarrod Marto, Danilo Pellin, Daniel E. Bauer, Scott A Armstrong, Pietro Genovese

Blood (2023) 142 (Supplement 1): 7130.

https://doi.org/10.1182/blood-2023-189980

Published: 2023

Journal Articles

Functional Dissection of Cellular Programs to Uncover Novel Gene Dependencies in AML

Jana M Ellegast, Gabriela Alexe, Subha Baniya, Amanda Hamze, Audrey Taillon, Biniam Adane, Amy Saur Conway, Tinghu Zhang, Nathanael S Gray, Scott A Armstrong, Kimberly Stegmaier

Blood (2023) 142 (Supplement 1): 1393.

https://doi.org/10.1182/blood-2023-189304

Published: 2023

Journal Articles

Menin Inhibitor Induced Menin Protein Degradation Contributes to Menin Inhibitor Efficacy

Jevon Cutler, Jonathan Tsai, Brandon Regalado, Wallace Bourgeois, Daniela Wenge, Jeonghyeon Kim, Radoslaw Nowak, Elizabeth Ener, Katherine Donovan, Sarah Naomi Olsen, Eric Fischer, Benjamin L. Ebert, Scott A Armstrong

Blood (2023) 142 (Supplement 1): 2788.

https://doi.org/10.1182/blood-2023-184931

Published: 2023

Journal Articles

Combining Menin and MEK Inhibition to Target Poor Prognostic KMT2A -Rearranged RAS Pathway-Mutant Acute Leukemia

Nastassja Scheidegger, Gabriela Alexe, Delan Khalid, Rhonda E Ries, Jim Wang, Todd A. Alonzo, Jennifer Perry, Scott A Armstrong, Soheil Meshinchi, Yana Pikman, Kimberly Stegmaier

Blood (2023) 142 (Supplement 1): 166.

https://doi.org/10.1182/blood-2023-185561

Published: 2023

Journal Articles

The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax

Johanna Rausch, Margarita M. Dzama, Nadezda Dolgikh, Hanna Stiller, Stephan Bohl, Catharina Lahrmann, Kerstin Kunz, Linda Kessler, Hakim Echchannaoui, Chun-Wei David Chen, Thomas Kindler, Francis Burrows, Matthias Theobald, Daniel Sasca, Scott A. Armstrong, Michael Kuehn

Blood (2022) 140 (Supplement 1): 6226–6227.

https://doi.org/10.1182/blood-2022-167566

Published: 2022

Journal Articles

UBR5 Is a Hect E3 Ubiquitin Ligase That Regulates Chromatin Bound Nuclear Hormone Receptor Stability

Blood (2022) 140 (Supplement 1): 2968–2969.

https://doi.org/10.1182/blood-2022-167615

Published: 2022

Journal Articles

Epigenetic Resistance to Menin-MLL1 Inhibition Is Driven By Loss of the Non-Canonical Polycomb Repressive Complex 1.1 in NUP98 -Rearranged AML

Emily B. Heikamp, Jill A Henrich, Hannah E Rice, Sanisha Mahendra-Rajah, Scott A. Armstrong

Blood (2022) 140 (Supplement 1): 95–96.

https://doi.org/10.1182/blood-2022-170165

Published: 2022

Journal Articles

Epitope Engineered Hematopoietic Stem and Progenitor Cells to Enable CAR-T Cell Immunotherapy for Acute Myeloid Leukemia

Gabriele Casirati, Andrea Cosentino, Adele Mucci, Iraxte Ugarte Zabala, Mohammed S. Mahmoud, Christian Brendel, Alessandro Rambaldi, Jerome Ritz, Scott A. Armstrong, Pietro Genovese

Blood (2022) 140 (Supplement 1): 303–304.

https://doi.org/10.1182/blood-2022-167285

Published: 2022

Journal Articles

Mutant NPM1 Is Recruited to MLL Target Genes Via Its Acidic Stretch and Nuclear Export Factor CRM1 and Regulates Oncogenic Transcription in Acute Myeloid Leukemia

Hannah J Uckelmann, Elena L Haarer, Reina Takeda, Eric Wong, Christian Marinaccio, Charles Hatton, Yanhe Wen, Florian Perner, Masooma Rajput, Noa J.C. Antonissen, Chun-Wei David Chen, Lorenzo Brunetti, Scott A. Armstrong

Blood (2022) 140 (Supplement 1): 5835–5836.

https://doi.org/10.1182/blood-2022-166630

Published: 2022

Journal Articles

The menin-MLL1 interaction is a molecular dependency in NUP98 -rearranged AML

Emily B. Heikamp, Jill A. Henrich, Florian Perner, Eric M. Wong, Charles Hatton, Yanhe Wen, Sonali P. Barwe, Anilkumar Gopalakrishnapillai, Haiming Xu, Hannah J. Uckelmann, Sumiko Takao, Yaniv Kazansky, Yana Pikman, Gerard M. McGeehan, Edward A. Kolb, Alex Kentsis, Scott A. Armstrong

Blood (2022) 139 (6): 894–906.

https://doi.org/10.1182/blood.2021012806

Published: 2022

Includes: Supplemental data

Journal Articles

Potent Ikaros Degradation By the Cereblon E3 Ligase Modulator CC-92480 Is Effective in Combination with Menin-MLL1 Inhibition in MLL1 -Rearranged and NPM1 -Mutant AML

Wallace Bourgeois, Brandon J. Aubrey, Jevon A. Cutler, Katherine A. Donovan, Charles Hatton, Alexandra C. P. Theall, Radoslaw P. Nowak, Gerard M. McGeehan, Eric S. Fischer, Scott A. Armstrong

Blood (2021) 138 (Supplement 1): 208.

https://doi.org/10.1182/blood-2021-150971

Published: 2021

Journal Articles

Inherited Blood Cancer Predisposition through Altered Transcription Elongation

Liam Cato, Jiawei Zhao, Erik L. Bao, Samuel Bryant, Nicholas Williams, Yuemeng Jia, Jyoti Nangalia, Michael Erb, Seychelle Vos, Scott A. Armstrong, Vijay G. Sankaran

Blood (2021) 138 (Supplement 1): 629.

https://doi.org/10.1182/blood-2021-153381

Published: 2021

Journal Articles

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

Blood (2021) 137 (24): 3403–3415.

https://doi.org/10.1182/blood.2020009023

Published: 2021

Includes: Supplemental data

Journal Articles

Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition

Margarita M. Dzama, Marlene Steiner, Johanna Rausch, Daniel Sasca, Jonas Schönfeld, Kerstin Kunz, Martha C. Taubert, Gerard M. McGeehan, Chun-Wei Chen, Annalisa Mupo, Patricia Hähnel, Matthias Theobald, Thomas Kindler, Richard P. Koche, George S. Vassiliou, Scott A. Armstrong, Michael W. M. Kühn

Blood (2020) 136 (21): 2442–2456.

https://doi.org/10.1182/blood.2020005037

Published: 2020

Includes: Supplemental data

Journal Articles

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts

Florian Perner, Jayant Y. Gadrey, Yijun Xiong, Charles Hatton, Benjamin K. Eschle, Andreas Weiss, Frédéric Stauffer, Christoph Gaul, Ralph Tiedt, Jennifer A. Perry, Scott A. Armstrong, Andrei V. Krivtsov

Blood (2020) 136 (17): 1983–1988.

https://doi.org/10.1182/blood.2020006113

Published: 2020

Includes: Supplemental data

Journal Articles

Rationale for Targeting BCL6 in MLL-Rearranged B-ALL

Lai N Chan, PhD, Christian Hurtz, PhD, Huimin Geng, PhD, Erica Ballabio, Gang Xiao, PhD, Gauri Deb, MS, PhD, Haytham Khoury, MD PhD, Scott A. Armstrong, MD PhD, Patricia Ernst, PhD, Ari Melnick, MD, Tom Arthur Milne, PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 1239.

https://doi.org/10.1182/blood-2019-131565

Published: 2019

NARROW

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A - and NPM1 -altered leukemias

PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A -r and NPM1c AML

BOD1L Facilitates Chromatin Binding of SETD1A and Promotes Leukemia Cell Growth

Epitope Edited Hematopoietic Stem Cells to Enable Synergistic Immunotherapy Combinations for Acute Myeloid Leukemia

Functional Dissection of Cellular Programs to Uncover Novel Gene Dependencies in AML

Menin Inhibitor Induced Menin Protein Degradation Contributes to Menin Inhibitor Efficacy

Combining Menin and MEK Inhibition to Target Poor Prognostic KMT2A -Rearranged RAS Pathway-Mutant Acute Leukemia

The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax

UBR5 Is a Hect E3 Ubiquitin Ligase That Regulates Chromatin Bound Nuclear Hormone Receptor Stability

Epigenetic Resistance to Menin-MLL1 Inhibition Is Driven By Loss of the Non-Canonical Polycomb Repressive Complex 1.1 in NUP98 -Rearranged AML

Epitope Engineered Hematopoietic Stem and Progenitor Cells to Enable CAR-T Cell Immunotherapy for Acute Myeloid Leukemia

Mutant NPM1 Is Recruited to MLL Target Genes Via Its Acidic Stretch and Nuclear Export Factor CRM1 and Regulates Oncogenic Transcription in Acute Myeloid Leukemia

The menin-MLL1 interaction is a molecular dependency in NUP98 -rearranged AML

Potent Ikaros Degradation By the Cereblon E3 Ligase Modulator CC-92480 Is Effective in Combination with Menin-MLL1 Inhibition in MLL1 -Rearranged and NPM1 -Mutant AML

Inherited Blood Cancer Predisposition through Altered Transcription Elongation

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts

Rationale for Targeting BCL6 in MLL-Rearranged B-ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only